Your fast track to the ultramodern lab

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI-supported workflow to optimize quality and response times, initially within prostate.

Your fast track to the ultramodern lab

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI-supported workflow to optimize quality and response times, initially within prostate.
Arrow Right

Your fast track to the ultramodern lab

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI-supported workflow to optimize quality and response times, initially within prostate.

Your fast track to the ultramodern lab

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI-supported workflow to optimize quality and response times, initially within prostate.
Meet the future of pathology
Arrow Right

How can an ultramodern laboratory, 100% specialized in uropathology, benefit you and your patients?

Your patient, our priority
Urologidagarna i Malmö, booth #43
Malmö Live
October 5–7, 2022 

Learn more about Inify Laboratories

Watch the video presentation

One out of seven will be diagnosed with prostate cancer

Handling of prostate biopsies makes up an increasing amount of workload for today’s pathology labs. Here, powerful decision support tools – such as Inify Prostate – have the potential to save valuable time for the pathologist, while ensuring a more objective, consistent and accurate evaluation of the biopsies.
PANEL TALK 

Successful first months of laboratory operation: Panel talk Q3 report 2023

Inify’s Q3 report is published and highlights continuous diagnostic operation and very positive feedback from customers. Inify’s CEO Fredrik Palm and Chief Medical Officer Claes Lindh talks about what this means for patients in practice in this panel talk together with Ole Eikeland.
For more panel discussions, please visit our YouTube channel
PANEL TALK 

Over 1,000 patients diagnosed: Panel talk Q2 report 2024

Inify reports sales of SEK 3.6 million in the quarter – up 62% compared to Q1. By the end of June, the laboratory had been open for over a year and had diagnosed more than 1,000 patients. More details about the laboratory operations and its success factors are discussed in a panel talk led by Ole Eikeland with Inify's CEO Fredrik Palm and Laboratory Director Emelie Edvigsson. 
For more panel discussions, please visit our YouTube channel

Follow our YouTube channel

Newsletter

Want to join us on our journey?
Let’s talk.